477 related articles for article (PubMed ID: 26233890)
61. Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma.
Zhu Y; Xu L; Zhang J; Xu W; Liu Y; Yin H; Lv T; An H; Liu L; He H; Zhang H; Liu J; Xu J; Lin Z
Cancer Sci; 2013 Jun; 104(6):663-71. PubMed ID: 23433103
[TBL] [Abstract][Full Text] [Related]
62. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
63. Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC.
Yadav RP; Chatterjee S; Chatterjee A; Pal DK; Ghosh S; Acharya K; Das M
J Recept Signal Transduct Res; 2022 Dec; 42(6):599-607. PubMed ID: 36125981
[TBL] [Abstract][Full Text] [Related]
64. Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma.
Gargalionis AN; Sarlani E; Stofas A; Malakou LS; Adamopoulos C; Bamias A; Boutati E; Constantinides CA; Stravodimos KG; Piperi C; Papavassiliou AG; Korkolopoulou P
Cancer Lett; 2020 Oct; 489():135-143. PubMed ID: 32561414
[TBL] [Abstract][Full Text] [Related]
65. ZNF471 Interacts with BANP to Reduce Tumour Malignancy by Inactivating PI3K/AKT/mTOR Signalling but is Frequently Silenced by Aberrant Promoter Methylation in Renal Cell Carcinoma.
Wang X; Yao L; Li Z; Zhang J; Ruan M; Mulati Y; Gan Y; Zhang Q
Int J Biol Sci; 2024; 20(2):643-663. PubMed ID: 38169650
[No Abstract] [Full Text] [Related]
66. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Zaryouh H; De Pauw I; Baysal H; Peeters M; Vermorken JB; Lardon F; Wouters A
Med Res Rev; 2022 Jan; 42(1):112-155. PubMed ID: 33928670
[TBL] [Abstract][Full Text] [Related]
67. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
Ghayad SE; Cohen PA
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
[TBL] [Abstract][Full Text] [Related]
68. Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway.
Wang N; Wang R; Tang J; Gao J; Fang Z; Zhang M; Shen X; Lu L; Chen Y
Contrast Media Mol Imaging; 2022; 2022():5602011. PubMed ID: 36176934
[TBL] [Abstract][Full Text] [Related]
69. Radix Actinidiae chinensis induces the autophagy and apoptosis in renal cell carcinoma cells.
Liu B; Yan Y; Zhang L
Eur J Med Res; 2024 May; 29(1):291. PubMed ID: 38764054
[TBL] [Abstract][Full Text] [Related]
70. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
71. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
72. Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas.
Su YC; Lee WC; Wang CC; Yeh SA; Chen WH; Chen PJ
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555391
[TBL] [Abstract][Full Text] [Related]
73. The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma.
Weissinger D; Tagscherer KE; Macher-Göppinger S; Haferkamp A; Wagener N; Roth W
Mol Cancer; 2013 Oct; 12(1):120. PubMed ID: 24107265
[TBL] [Abstract][Full Text] [Related]
74. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
[TBL] [Abstract][Full Text] [Related]
75. Marine compounds targeting the PI3K/Akt signaling pathway in cancer therapy.
Wei J; Gou Z; Wen Y; Luo Q; Huang Z
Biomed Pharmacother; 2020 Sep; 129():110484. PubMed ID: 32768966
[TBL] [Abstract][Full Text] [Related]
76. Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer.
Meuten TK; Dean GA; Thamm DH
Vet Pathol; 2024 May; 61(3):339-356. PubMed ID: 37905509
[TBL] [Abstract][Full Text] [Related]
77. [Effect of licochalcone A on autophagy in renal cell carcinoma via PI3K/Akt/mTOR signaling pathway].
Xin H; Xu W
Zhongguo Zhong Yao Za Zhi; 2018 Sep; 43(17):3545-3552. PubMed ID: 30347925
[TBL] [Abstract][Full Text] [Related]
78. The PI3K/AKT pathway in the pathogenesis of prostate cancer.
Chen H; Zhou L; Wu X; Li R; Wen J; Sha J; Wen X
Front Biosci (Landmark Ed); 2016 Jun; 21(5):1084-91. PubMed ID: 27100493
[TBL] [Abstract][Full Text] [Related]
79. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.
Kearney AY; Fan YH; Giri U; Saigal B; Gandhi V; Heymach JV; Zurita AJ
PLoS One; 2015; 10(8):e0135962. PubMed ID: 26313261
[TBL] [Abstract][Full Text] [Related]
80. Curcumin Promotes Cell Cycle Arrest and Inhibits Survival of Human Renal Cancer Cells by Negative Modulation of the PI3K/AKT Signaling Pathway.
Zhang H; Xu W; Li B; Zhang K; Wu Y; Xu H; Wang J; Zhang J; Fan R; Wei J
Cell Biochem Biophys; 2015 Dec; 73(3):681-6. PubMed ID: 27259310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
